Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRel: REOLYSIN in Relapsed/Refractory Multiple Myeloma
NCT03015922Phase 1Unknown
- Sponsor
- University of Leeds
- Start
- Jun 2017
- Primary completion
- Sep 2021
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelareorep in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoint: Dose-limiting toxicities at 28 days. Status: unknown.
02
Drugs
pelareorep
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03015922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015922.